Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
NCT02098473 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2017-05-09
Summary
The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.
Conditions
- Eosinophilic Esophagitis
Interventions
- DRUG
-
RPC4046
- DRUG
Sponsors & Collaborators
-
Celgene
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-08-31
- Primary Completion
- 2016-02-17
- Completion
- 2017-01-30
Countries
- United States
- Canada
- Switzerland
Study Locations
More Related Trials
-
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
NCT04656275 ·Status: TERMINATED ·Phase: PHASE1
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
NCT05628740 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis
NCT02950805 ·Status: COMPLETED ·Phase: PHASE1
-
PH-797804 LPS Study in Healthy Volunteers
NCT02084485 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects
NCT02058407 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
NCT04631016 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
NCT00769119 ·Status: COMPLETED ·Phase: PHASE2
-
This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.
NCT03422068 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT04419506 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01254409 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
NCT02715570 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
NCT05154240 ·Status: COMPLETED ·Phase: PHASE1
-
A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
NCT05032066 ·Status: TERMINATED ·Phase: PHASE2
-
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
NCT05674994 ·Status: RECRUITING ·Phase: PHASE3
-
Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
NCT03928847 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
NCT04093024 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma
NCT04576325 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
NCT05327803 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01529853 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
NCT04400318 ·Status: COMPLETED ·Phase: PHASE4
-
Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.
NCT03884842 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
NCT03711162 ·Status: TERMINATED ·Phase: PHASE3
-
Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function
NCT05625347 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
NCT02846324 ·Status: COMPLETED ·Phase: PHASE2